XNAS
ALT
Market cap505mUSD
Oct 08, Last price
2.60USD
1D
-2.26%
1Q
-14.75%
Jan 2017
-99.73%
IPO
-99.88%
Name
Altimmune Inc
Chart & performance
P/E
—
P/S
12,332.50
EPS
—
Div yield, %
—
Shrs. gr., 5y
28.00%
Rev. gr., 5y
-65.33%
Revenues
41k
+105.00%
Net income
-88m
L-7.33%
CFO
-68m
L-15.42%
Dividend
Jan 20, 2017291.0033 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Key people
Chairman of the Board, President, Chief Executive Officer · since 2026
Chief Financial Officer · since 2024
M. Scot Roberts
Chief Scientific Officer · since 2017
Raymond Jordt
Chief Business Officer · since 2023
Linda Richardson
Chief Commercial Officer · since 2025
Vipin Garg
President, Chief Executive Officer, Director · since 2018
Teri Lawver
Director · since 2025
John Gill
Independent Director · since 2017
Philip Hodges
Independent Director · since 2017
Diane Jorkasky
Independent Director · since 2020
Independent Director · since 2018
Mitchel Sayare
Independent Director · since 2025
Klaus Schafer
Independent Director · since 2017
Legal address
c/o National Registered Agents, Inc., 1209 ORANGE STREET
WILMINGTON, DE 19801
US
WILMINGTON, DE 19801
US
Headquarters
910 Clopper Road; Suite 201S
Gaithersburg, MD 20878
US
Gaithersburg, MD 20878
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||